Loading...

BPHY

BIOPHYTIS SA

()

2024 6-K

Financial Statement Delay

30 Apr '26

Participation Announcement

26 Mar '26

Capital Increase Completed

11 Mar '26

Bond Financing Update

27 Feb '26

Strategic Agreement

28 Jan '26

General Meeting Results

14 Nov '25

Interim Financial Report

31 Oct '25

Phase-3 Trial Launch

14 Oct '25

Funding Secured

15 Sep '25

Phase 3 Trial Announcement

11 Sep '25

New Clinical Trial

3 Sep '25

Obesity Trial Strategy

2 Sep '25

Regulatory Approval

28 Aug '25

Bond Debt Completion

6 Aug '25

2024 Financial Report

25 Jul '25

Strategic Partnership

18 Jul '25

Legal Victory

18 Jul '25

Conference Participation

17 Jul '25

Financial Results Released

11 Jul '25

BIO Convention Success

9 Jul '25

Delayed Accounts Release

3 Jul '25

Share Trading Halt

24 Jun '25

Event Participation

4 Jun '25

Financial Reporting Delay

2 Jun '25

Event Announcement

15 May '25

Financial Statement Delay

29 Apr '25

Mobility Restoration Target

22 Apr '25

Clinical Trial Launch

9 Apr '25

Private Placement Completed

31 Mar '25

Funding Success

26 Mar '25

Co-Development Agreement

20 Mar '25

License Negotiation

14 Jan '25

Funding Announcement

8 Jan '25

Share Suspension

6 Jan '25

Interim Financial Report

30 Sep '24

Partnership Announcement

22 Jul '24

FDA Approval News

11 Jul '24

COVA Study Results

1 Jul '24

General Meeting Approval

26 Jun '24

Exclusive Deal Announced

20 Jun '24

Contract Extension

20 Jun '24

Production Success

14 Jun '24

FDA Application Filed

11 Jun '24

General Meeting Notice

7 Jun '24

Obesity Study Announcement

14 May '24

Partner Search Strategy

29 Apr '24

ADS Transfer Report

25 Apr '24

ADR Ratio Change

19 Apr '24

New Advisory Board

18 Apr '24

Patent Application Filed

15 Apr '24

Financial Results Update

9 Apr '24

Clinical Study Launch

9 Apr '24

General Meeting Results

5 Apr '24

Press Release Update

22 Mar '24

Stock Split Announcement

18 Mar '24

Meeting Announcement

18 Mar '24

Event Participation Announced

12 Mar '24

Clinical Trial Results

8 Mar '24

Longevity Book Release

22 Feb '24

COVA Study Results

5 Jan '24

Funding Update

5 Jan '24

External Links:

SEC

On June 20, 2024, Biophytis S.A. announced it granted Blanver exclusive rights to BIO101 in Latin America, valued at €108 million. This is a significant event for the company.

AI Assistant

BIOPHYTIS SA

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.